NP

Your Article Summary

See Latest Articles

A double-blind, randomized, saline-controlled study of the efficacy and safety of Euflexxa® for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial)
Seminars in Arthritis and Rheumatism, 06/29/09

Altman RD et al. – Study demonstrates that Euflexxa (1% sodium hyaluronate; IA-BioHA) therapy resulted in significant osteoarthritis (OA) knee pain relief at 26 weeks compared with intra-articular saline (IA-SA). Subjects treated with IA-BioHA also experienced significant improvements in joint function, treatment satisfaction, and HRQoL.

• FLEXX trial: assessing the safety and efficacy of IA-BioHA therapy for knee OA at 26 wks
• Subjects with chronic knee OA were randomized to 3 weekly IA injections IA-SA or IA-BioHA (20 mg/2 ml)
• Primary efficacy outcome: subject recorded difference in least-squares means between IA-BioHA and IA-SA following a 50-foot walk test, measured via 100-mm VAS
• Secondary outcome measures:
  • Osteoarthritis Research Society International responder index
  • Western Ontario McMaster University Osteoarthritis Index VA 3.1 subscales
  • Patient global assessment
  • Rescue medication, and
  • Health-related quality of life (HRQoL) by the SF-36
• Safety assessed by monitoring and reporting vital signs, physical examination of the target knee following injection, adverse events, and concomitant medications

• 588 subjects randomized to either IA-BioHA (n=293) or IA-SA (n=295), with an 88% 26 wk completion rate
• No differences were noted between the treatment groups at baseline
• In the IA-BioHA group, mean VAS scores decreased by 25.7 mm, vs 18.5 mm in the IA-SA group
• This corresponded to a median reduction of 53% from baseline for IA-BioHA and a 38% reduction for IA-SA
• The difference in least-squares means was -6.6 mm
• Secondary outcome measures were consistent
• Both IA-SA and IA-BioHA injections were well tolerated, with a low incidence of AEs
• Injection-site reactions were reported by 1 (<1%) subject in the IA-SA group and 2 (1%) in the IA-BioHA group

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

See All of Clinical Pharmacology